Bad time for Bonzo? Experimental models of hepatitis C virus infection, replication, and pathogenesis
2001; Lippincott Williams & Wilkins; Volume: 33; Issue: 3 Linguagem: Inglês
10.1053/jhep.2001.23041
ISSN1527-3350
Autores Tópico(s)Liver Disease Diagnosis and Treatment
ResumoHepatologyVolume 33, Issue 3 p. 489-495 Concise ReviewFree Access Bad time for Bonzo? Experimental models of hepatitis C virus infection, replication, and pathogenesis Arash Grakoui, Arash Grakoui From the Center for the Study of Hepatitis C, Laboratory for Virology and Infectious Disease, The Rockefeller University, New York, NYSearch for more papers by this authorHolly L. Hanson, Holly L. Hanson From the Center for the Study of Hepatitis C, Laboratory for Virology and Infectious Disease, The Rockefeller University, New York, NYSearch for more papers by this authorCharles M. Rice, Corresponding Author Charles M. Rice [email protected] From the Center for the Study of Hepatitis C, Laboratory for Virology and Infectious Disease, The Rockefeller University, New York, NYCenter for the Study of Hepatitis C, Laboratory for Virology and Infectious Disease, The Rockefeller University, 1230 York Ave., New York, NY 10021-6399.===Search for more papers by this author Arash Grakoui, Arash Grakoui From the Center for the Study of Hepatitis C, Laboratory for Virology and Infectious Disease, The Rockefeller University, New York, NYSearch for more papers by this authorHolly L. Hanson, Holly L. Hanson From the Center for the Study of Hepatitis C, Laboratory for Virology and Infectious Disease, The Rockefeller University, New York, NYSearch for more papers by this authorCharles M. Rice, Corresponding Author Charles M. Rice [email protected] From the Center for the Study of Hepatitis C, Laboratory for Virology and Infectious Disease, The Rockefeller University, New York, NYCenter for the Study of Hepatitis C, Laboratory for Virology and Infectious Disease, The Rockefeller University, 1230 York Ave., New York, NY 10021-6399.===Search for more papers by this author First published: 30 December 2003 https://doi.org/10.1053/jhep.2001.23041Citations: 39AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Fishman JA, Rubin RH, Koziel MJ, Periera BJ. Hepatitis C virus and organ transplantation. Transplantation 1996; 62: 147–154. MEDLINE 10.1097/00007890-199607270-00001 CASPubMedWeb of Science®Google Scholar 2 Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327: 1899–1905. MEDLINE 10.1056/NEJM199212313272702 CASPubMedWeb of Science®Google Scholar 3 Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556–562. MEDLINE 10.1056/NEJM199908193410802 CASPubMedWeb of Science®Google Scholar 4 Rice CM. Flaviviridae: the viruses and their replication. In: BN Fields, DM Knipe, PM Howley, eds. Fields Virology. Third ed. Philadelphia: Lippincott-Raven, 1996: 931–960. Web of Science®Google Scholar 5 Reichard O, Schvarcz R, Weiland O. Therapy of hepatitis C: alpha interferon and ribavirin. Hepatology 1997; 26(Suppl): 108S–111S. MEDLINE 10.1002/hep.510260719 CASPubMedWeb of Science®Google Scholar 6 Alter HJ, Purcell RH, Holland PV, Popper H. Transmissible agent in non-A, non-B hepatitis. Lancet 1978; 1: 459–463. MEDLINE 10.1016/S0140-6736(78)90131-9 CASPubMedWeb of Science®Google Scholar 7 Hollinger FB, Gitnick G, Aach RD, Szmuness W, Mosley JW, Stevens CE, Peters RL, et al. Non-A, non-B hepatitis transmission in chimpanzees: A project of the transfusion-transmitted viruses study group. Intervirology 1978; 10: 60–68. MEDLINE 10.1159/000148969 CASPubMedWeb of Science®Google Scholar 8 Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359–362. MEDLINE 10.1126/science.2523562 CASPubMedWeb of Science®Google Scholar 9 Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, Guardia J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992; 66: 3225–3229. MEDLINE 10.1128/JVI.66.5.3225-3229.1992 CASPubMedWeb of Science®Google Scholar 10 Klenerman P, Lechner F, Kantzanou M, Ciurea A, Hengartner H, Zinkernagel R. Viral escape and the failure of cellular immune responses. Science 2000; 289: 2003. MEDLINE 10.1126/science.289.5487.2003a CASPubMedGoogle Scholar 11 Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288: 339–344. MEDLINE 10.1126/science.288.5464.339 CASPubMedWeb of Science®Google Scholar 12 Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol 2000; 81: 1631–1648. MEDLINE 10.1099/0022-1317-81-7-1631 CASPubMedWeb of Science®Google Scholar 13 Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290: 1972–1975. MEDLINE 10.1126/science.290.5498.1972 CASPubMedWeb of Science®Google Scholar 14 Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110–113. MEDLINE 10.1126/science.285.5424.110 CASPubMedWeb of Science®Google Scholar 15 Barker LF, Maynard JE, Purcell RH, Hoofnagle JH, Berquist KR, London WT. Viral hepatitis, type B, in experimental animals. Am J Med Sci 1975; 270: 189–195. MEDLINE 10.1097/00000441-197507000-00026 CASPubMedWeb of Science®Google Scholar 16 Karron RA, Daemer R, Ticehurst J, D'Hondt E, Popper H, Mihalik K, Phillips J, et al. Studies of prototype live hepatitis A virus vaccines in primate models. J Infect Dis 1988; 157: 338–345. MEDLINE 10.1093/infdis/157.2.338 CASPubMedWeb of Science®Google Scholar 17 Maynard JE, Lorenz D, Bradley DW, Feinstone SM, Krushak DH, Barker LF, Purcell RH. Review of infectivity studies in nonhuman primates with virus-like particles associated with MS-1 hepatitis. Am J Med Sci 1975; 270: 81–85. MEDLINE 10.1097/00000441-197507000-00012 CASPubMedWeb of Science®Google Scholar 18 Purcell RH, Gerin JL. Hepatitis B subunit vaccine: a preliminary report of safety and efficacy tests in chimpanzees. Am J Med Sci 1975; 270: 395–399. MEDLINE 10.1097/00000441-197509000-00024 CASPubMedWeb of Science®Google Scholar 19 Rizzetto M, Canese MG, Gerin JL, London WT, Sly DL, Purcell RH. Transmission of the hepatitis B virus-associated delta antigen to chimpanzees. J Infect Dis 1980; 141: 590–602. MEDLINE 10.1093/infdis/141.5.590 CASPubMedWeb of Science®Google Scholar 20 Tabor E, Garety RJ, Drucker JA, Seeff LB, Hoofnagle JF, Jackson DR, April M, et al. Transmission of non-A, non-B hepatitis from man to chimpanzee. Lancet 1978; 1: 463–466. MEDLINE 10.1016/S0140-6736(78)90132-0 CASPubMedWeb of Science®Google Scholar 21 Tabor E, April M, Seeff LB, Gerety RJ. Acute non-A, non-B hepatitis. Prolonged presence of the infectious agent in blood. Gastroenterology 1979; 76: 680–684. MEDLINE CASPubMedWeb of Science®Google Scholar 22 He LF, Alling D, Popkin T, Shapiro M, Alter HJ, Purcell RH. Determining the size of non-A, non-B hepatitis virus by filtration. J Infect Dis 1987; 156: 636–640. MEDLINE 10.1093/infdis/156.4.636 CASPubMedWeb of Science®Google Scholar 23 Yuasa T, Ishikawa G, Manabe S, Sekiguchi S, Takeuchi K, Miyamura T. The particle size of hepatitis C virus estimated by filtration through microporous regenerated cellulose fibre. J Gen Virol 1991; 72: 2021–2024. MEDLINE 10.1099/0022-1317-72-8-2021 CASPubMedWeb of Science®Google Scholar 24 Tabor E, Gerety RJ. Inactivation of an agent of human non-A, non-B hepatitis by formalin. J Infect Dis 1980; 142: 767–770. MEDLINE 10.1093/infdis/142.5.767 CASPubMedWeb of Science®Google Scholar 25 Yoshizawa H, Itoh Y, Iwakiri S, Kitajima K, Tanaka A, Tachibana T, Nakamura T, et al. Non-A, non-B (type 1) hepatitis agent capable of inducing tubular ultrastructures in the hepatocyte cytoplasm of chimpanzees: inactivation by formalin and heat. Gastroenterology 1982; 82: 502–506. MEDLINE PubMedWeb of Science®Google Scholar 26 Purcell RH, Gerin JL, Popper H, London WT, Cicmanec J, Eichberg JW, Newman J, et al. Hepatitis B virus, hepatitis non-A, non-B virus and hepatitis delta virus in lyophilized antihemophilic factor: relative sensitivity to heat. Hepatology 1985; 5: 1091–1099. MEDLINE 10.1002/hep.1840050606 PubMedWeb of Science®Google Scholar 27 Heinrich D, Kotitschke R, Berthold H. Clinical evaluation of the hepatitis safety of a beta- propiolactone/ultraviolet treated factor IX concentrate (PPSB). Thromb Res 1982; 28: 75–83. MEDLINE 10.1016/0049-3848(82)90035-4 CASPubMedWeb of Science®Google Scholar 28 Bradley DW, Maynard JE, Popper H, Cook EH, Ebert JW, McCaustland KA, Schable CA, et al. Posttransfusion non-A, non-B hepatitis: physicochemical properties of two distinct agents. J Infect Dis 1983; 148: 254–265. MEDLINE 10.1093/infdis/148.2.254 PubMedWeb of Science®Google Scholar 29 Feinstone SM, Mihalik KB, Kamimura T, Alter HJ, London WT, Purcell RH. Inactivation of hepatitis B virus and non-A, non-B hepatitis by chloroform. Infect Immun 1983; 41: 816–821. MEDLINE 10.1128/IAI.41.2.816-821.1983 CASPubMedWeb of Science®Google Scholar 30 Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, Rice CM. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 1997; 277: 570–574. MEDLINE 10.1126/science.277.5325.570 CASPubMedWeb of Science®Google Scholar 31 Yanagi M, Purcell RH, Emerson SU, Bukh J. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci U S A 1997; 94: 8738–8743. MEDLINE 10.1073/pnas.94.16.8738 CASPubMedWeb of Science®Google Scholar 32 Farci P, London WT, Wong DC, Dawson GJ, Vallari DS, Engle R, Purcell RH. The natural history of infection with hepatitis C virus (HCV) in chimpanzees: comparison of serologic responses measured with first- and second-generation assays and relationship to HCV viremia. J Infect Dis 1992; 165: 1006–1011. MEDLINE 10.1093/infdis/165.6.1006 CASPubMedWeb of Science®Google Scholar 33 Shimizu YK, Weiner AJ, Rosenblatt J, Wong DC, Shapiro M, Popkin T, Houghton M, et al. Early events in hepatitis C virus infection of chimpanzees. Proc Natl Acad Sci U S A 1990; 87: 6441–6444. MEDLINE 10.1073/pnas.87.16.6441 CASPubMedWeb of Science®Google Scholar 34 Abe K, Inchauspe G, Shikata T, Prince AM. Three different patterns of hepatitis C virus infection in chimpanzees. Hepatology 1992; 15: 690–695. MEDLINE 10.1002/hep.1840150423 CASPubMedWeb of Science®Google Scholar 35 Walker CM. Comparative features of hepatitis C virus infection in humans and chimpanzees. Springer Semin Immunopathol 1997; 19: 85–98. MEDLINE 10.1007/BF00945027 CASPubMedWeb of Science®Google Scholar 36 Ogata N, Alter HJ, Miller RH, Purcell RH. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci U S A 1991; 88: 3392–3396. MEDLINE 10.1073/pnas.88.8.3392 CASPubMedWeb of Science®Google Scholar 37 Muchmore E, Popper H, Peterson DA, Miller MF, Lieberman HM. Non-A, non-B hepatitis-related hepatocellular carcinoma in a chimpanzee. J Med Primatol 1988; 17: 235–246. MEDLINE 10.1111/j.1600-0684.1988.tb00386.x CASPubMedWeb of Science®Google Scholar 38 Bradley DW, Maynard JE, Popper H, Ebert JW, Cook EH, Fields HA, Kemler BJ. Persistent non-A, non-B hepatitis in experimentally infected chimpanzees. J Infect Dis 1981; 143: 210–218. MEDLINE 10.1093/infdis/143.2.210 CASPubMedWeb of Science®Google Scholar 39 Seeff LB. Natural history of viral hepatitis, type C. Semin Gastrointest Dis 1995; 6: 20–27. MEDLINE PubMedGoogle Scholar 40 Shimizu YK, Feinstone SM, Purcell RH, Alter HJ, London WT. Non-A, non-B hepatitis: ultrastructural evidence for two agents in experimentally infected chimpanzees. Science 1979; 205: 197–200. MEDLINE 10.1126/science.451589 CASPubMedWeb of Science®Google Scholar 41 Erickson AL, Houghton M, Choo QL, Weiner AJ, Ralston R, Muchmore E, Walker CM. Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. J Immunol 1993; 151: 4189–4199. MEDLINE CASPubMedWeb of Science®Google Scholar 42 Shindo M, Di Bisceglie AM, Biswas R, Mihalik K, Feinstone SM. Hepatitis C virus replication during acute infection in the chimpanzee. J Infect Dis 1992; 166: 424–427. MEDLINE 10.1093/infdis/166.2.424 CASPubMedWeb of Science®Google Scholar 43 Prince AM, Brotman B, Huima T, Pascual D, Jaffery M, Inchauspe G. Immunity in hepatitis C infection. J Infect Dis 1992; 165: 438–443. MEDLINE 10.1093/infdis/165.3.438 CASPubMedWeb of Science®Google Scholar 44 Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, Mushahwar IK, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258: 135–140. MEDLINE 10.1126/science.1279801 CASPubMedWeb of Science®Google Scholar 45 Choo Q-L, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, Han J, et al. Vaccination of chimpanzees against infection by the hepatitis C virus Proc Natl Acad Sci U S A 1994; 91: 1294–1298. 10.1073/pnas.91.4.1294 CASPubMedWeb of Science®Google Scholar 46 Collier J, Heathcote J. Hepatitis C viral infection in the immunosuppressed patient. Hepatology 1998; 27: 2–6. MEDLINE 10.1002/hep.510270102 CASPubMedWeb of Science®Google Scholar 47 Bjorkander J, Cunningham-Rundles C, Lundin P, Olsson R, Soderstrom R, Hanson LA. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. Am J Med 1988; 84: 107–111. MEDLINE 10.1016/0002-9343(88)90016-2 CASPubMedWeb of Science®Google Scholar 48 Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994; 331: 1607–1611. MEDLINE 10.1056/NEJM199412153312402 CASPubMedWeb of Science®Google Scholar 49 Gruber A, Lundberg LG, Bjorkholm M. Reactivation of chronic hepatitis C after withdrawal of immunosuppressive therapy. J Intern Med 1993; 234: 223–225. MEDLINE 10.1111/j.1365-2796.1993.tb00734.x CASPubMedWeb of Science®Google Scholar 50 Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, Houghton M, et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999; 10: 439–449. MEDLINE 10.1016/S1074-7613(00)80044-8 CASPubMedWeb of Science®Google Scholar 51 Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, Rumi MG, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996; 98: 706–714. MEDLINE 10.1172/JCI118842 CASPubMedWeb of Science®Google Scholar 52 Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999; 30: 595–601. MEDLINE 10.1002/hep.510300312 CASPubMedWeb of Science®Google Scholar 53 Diepolder HM, Gerlach JT, Zachoval R, Hoffmann RM, Jung MC, Wierenga EA, Scholz S, et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 1997; 71: 6011–6019. MEDLINE 10.1128/JVI.71.8.6011-6019.1997 CASPubMedWeb of Science®Google Scholar 54 Diepolder HM, Zachoval R, Hoffmann RM, Jung MC, Gerlach T, Pape GR. The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis C. J Mol Med 1996; 74: 583–588. MEDLINE 10.1007/s001090050062 CASPubMedWeb of Science®Google Scholar 55 Cerny A, McHutchison JG, Pasquinelli C, Brown ME, Brothers MA, Grabscheid B, Fowler P, et al. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 1995; 95: 521–530. MEDLINE 10.1172/JCI117694 CASPubMedWeb of Science®Google Scholar 56 Rehermann B, Chang KM, McHutchison JG, Kokka R, Houghton M, Chisari FV. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest 1996; 98: 1432–1440. MEDLINE 10.1172/JCI118931 CASPubMedWeb of Science®Google Scholar 57 Hiroishi K, Kita H, Kojima M, Okamoto H, Moriyama T, Kaneko T, Ishikawa T, et al. Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection. Hepatology 1997; 25: 705–712. MEDLINE 10.1002/hep.510250336 CASPubMedWeb of Science®Google Scholar 58 Abe K, Kurata T, Teramoto Y, Shiga J, Shikata T. Lack of susceptibility of various primates and woodchucks to hepatitis C virus. J Med Primatol 1993; 22: 433–434. MEDLINE 10.1111/j.1600-0684.1993.tb00697.x CASPubMedWeb of Science®Google Scholar 59 Xie ZC, Riezu-Boj JI, Lasarte JJ, Guillen J, Su JH, Civeira MP, Prieto J. Transmission of hepatitis C virus infection to tree shrews. Virology 1998; 244: 513–520. MEDLINE 10.1006/viro.1998.9127 CASPubMedWeb of Science®Google Scholar 60 Feinstone SM, Alter HJ, Dienes HP, Shimizu Y, Popper H, Blackmore D, Sly D, et al. Non-A, non-B hepatitis in chimpanzees and marmosets. J Infect Dis 1981; 144: 588–598. MEDLINE 10.1093/infdis/144.6.588 CASPubMedWeb of Science®Google Scholar 61 Watanabe T, Katagiri J, Kojima H, Kamimura T, Ichida F, Ashida M, Hamada C, et al. Studies on transmission of human non-A, non-B hepatitis to marmosets. J Med Virol 1987; 22: 143–156. MEDLINE 10.1002/jmv.1890220205 CASPubMedWeb of Science®Google Scholar 62 Karayiannis P, Scheuer PJ, Bamber M, Cohn D, Hurn BA, Thomas HC. Experimental infection of Tamarins with human non-A, non-B hepatitis virus. J Med Virol 1983; 11: 251–256. MEDLINE 10.1002/jmv.1890110308 CASPubMedWeb of Science®Google Scholar 63 Garson JA, Whitby K, Watkins P, Morgan AJ. Lack of susceptibility of the cottontop tamarin to hepatitis C infection. J Med Virol 1997; 52: 286–288. MEDLINE 10.1002/(SICI)1096-9071(199707)52:3 3.0.CO;2-Z CASPubMedWeb of Science®Google Scholar 64 Bukh J, Apgar CL, Yanagi M. Toward a surrogate model for hepatitis C virus: an infectious molecular clone of the GB virus-B hepatitis agent. Virology 1999; 262: 470–478. MEDLINE 10.1006/viro.1999.9941 CASPubMedWeb of Science®Google Scholar 65 Beames B, Chavez D, Guerra B, Notvall L, Brasky KM, Lanford RE. Development of a primary tamarin hepatocyte culture system for GB virus- B: a surrogate model for hepatitis C virus. J Virol 2000; 74: 11764–11772. MEDLINE 10.1128/JVI.74.24.11764-11772.2000 CASPubMedWeb of Science®Google Scholar 66 Hahm B, Back SH, Lee TG, Wimmer E, Jang SK. Generation of a novel poliovirus with a requirement of hepatitis C virus protease NS3 activity. Virology 1996; 226: 318–326. MEDLINE 10.1006/viro.1996.0659 CASPubMedWeb of Science®Google Scholar 67 Cho YG, Moon HS, Sung YC. Construction of hepatitis C-SIN virus recombinants with replicative dependency on hepatitis C virus serine protease activity. J Virol Methods 1997; 65: 201–207. MEDLINE 10.1016/S0166-0934(97)02183-6 CASPubMedWeb of Science®Google Scholar 68 Filocamo G, Pacini L, Migliaccio G. Chimeric Sindbis viruses dependent on the NS3 protease of hepatitis C virus. J Virol 1997; 71: 1417–1427. MEDLINE CASPubMedWeb of Science®Google Scholar 69 Lai VC, Zhong W, Skelton A, Ingravallo P, Vassilev V, Donis RO, Hong Z, et al. Generation and characterization of a hepatitis C virus NS3 protease- dependent bovine viral diarrhea virus. J Virol 2000; 74: 6339–6347. MEDLINE 10.1128/JVI.74.14.6339-6347.2000 CASPubMedWeb of Science®Google Scholar 70 Frolov I, McBride MS, Rice CM. cis-acting RNA elements required for replication of bovine viral diarrhea virus-hepatitis C virus 5′ nontranslated region chimeras. RNA 1998; 4: 1418–1435. MEDLINE 10.1017/S1355838298981031 CASPubMedWeb of Science®Google Scholar 71 Lu HH, Wimmer E. Poliovirus chimeras replicating under the translational control of genetic elements of hepatitis C virus reveal unusual properties of the internal ribosomal entry site of hepatitis C virus. Proc Natl Acad Sci U S A 1996; 93: 1412–1417. MEDLINE 10.1073/pnas.93.4.1412 CASPubMedWeb of Science®Google Scholar 72 Zhao WD, Wimmer E, Lahser FC. Poliovirus/Hepatitis C virus (internal ribosomal entry site-core) chimeric viruses: improved growth properties through modification of a proteolytic cleavage site and requirement for core RNA sequences but not for core-related polypeptides. J Virol 1999; 73: 1546–1554. MEDLINE 10.1128/JVI.73.2.1546-1554.1999 CASPubMedWeb of Science®Google Scholar 73 Macejak DG, Jensen KL, Jamison SF, Domenico K, Roberts EC, Chaudhary N, von Carlowitz I, et al. Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes. Hepatology 2000; 31: 769–776. MEDLINE 10.1002/hep.510310331 CASPubMedWeb of Science®Google Scholar 74 Das S, Ott M, Yamane A, Tsai W, Gromeier M, Lahser F, Gupta S, et al. A small yeast RNA blocks hepatitis C virus internal ribosome entry site (HCV IRES)-mediated translation and inhibits replication of a chimeric poliovirus under translational control of the HCV IRES element [published erratum appears in J Virol 1998;72:9419]. J Virol 1998; 72: 5638–5647. MEDLINE CASPubMedWeb of Science®Google Scholar 75 Zhang H, Hanecak R, Brown-Driver V, Azad R, Conklin B, Fox MC, Anderson KP. Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. Antimicrob Agents Chemother 1999; 43: 347–353. MEDLINE CASPubMedWeb of Science®Google Scholar 76 Yanagi M, St. Claire M, Shapiro M, Emerson SU, Purcell RH, Bukh J. Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo. Virology 1998; 244: 161–172. MEDLINE 10.1006/viro.1998.9092 CASPubMedWeb of Science®Google Scholar 77 Yanagi M, Purcell RH, Emerson SU, Bukh J. Hepatitis C virus: an infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras. Virology 1999; 262: 250–263. MEDLINE 10.1006/viro.1999.9889 CASPubMedWeb of Science®Google Scholar 78 Chisari FV. Hepatitis B virus transgenic mice: models of viral immunobiology and pathogenesis. Curr Top Microbiol Immunol 1996; 206: 149–173. MEDLINE 10.1007/978-3-642-85208-4_9 CASPubMedWeb of Science®Google Scholar 79 Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, Miyamura T, et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997; 78: 1527–1531. MEDLINE 10.1099/0022-1317-78-7-1527 CASPubMedWeb of Science®Google Scholar 80 Koike K, Moriya K, Ishibashi K, Matsuura Y, Suzuki T, Saito I, Iino S, et al. Expression of hepatitis C virus envelope proteins in transgenic mice. J Gen Virol 1995; 76: 3031–3038. MEDLINE 10.1099/0022-1317-76-12-3031 CASPubMedWeb of Science®Google Scholar 81 Kawamura T, Furusaka A, Koziel MJ, Chung RT, Wang TC, Schmidt EV, Liang TJ. Transgenic expression of hepatitis C virus structural proteins in the mouse. Hepatology 1997; 25: 1014–1021. MEDLINE 10.1002/hep.510250437 CASPubMedWeb of Science®Google Scholar 82 Pasquinelli C, Shoenberger JM, Chung J, Chang KM, Guidotti LG, Selby M, Berger K, et al. Hepatitis C virus core and E2 protein expression in transgenic mice. Hepatology 1997; 25: 719–727. MEDLINE 10.1002/hep.510250338 CASPubMedWeb of Science®Google Scholar 83 Honda A, Arai Y, Hirota N, Sato T, Ikegaki J, Koizumi T, Hatano M, et al. Hepatitis C virus structural proteins induce liver cell injury in transgenic mice. J Med Virol 1999; 59: 281–289. MEDLINE 10.1002/(SICI)1096-9071(199911)59:3 3.0.CO;2-S CASPubMedWeb of Science®Google Scholar 84 Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nature Medicine 1998; 4: 1065–1067. MEDLINE 10.1038/2053 CASPubMedWeb of Science®Google Scholar 85 Wakita T, Taya C, Katsume A, Kato J, Yonekawa H, Kanegae Y, Saito I, et al. Efficient conditional transgene expression in hepatitis C virus cDNA transgenic mice mediated by the Cre/loxP system. J Biol Chem 1998; 273: 9001–9006. MEDLINE 10.1074/jbc.273.15.9001 CASPubMedWeb of Science®Google Scholar 86 Wakita T, Katsume A, Kato J, Taya C, Yonekawa H, Kanegae Y, Saito I, et al. Possible role of cytotoxic T cells in acute liver injury in hepatitis C virus cDNA transgenic mice mediated by Cre/loxP system. J Med Virol 2000; 62: 308–317. MEDLINE 10.1002/1096-9071(200011)62:3 3.0.CO;2-6 CASPubMedWeb of Science®Google Scholar 87 Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, et al. Binding of hepatitis C virus to CD81. Science 1998; 282: 938–941. MEDLINE 10.1126/science.282.5390.938 CASPubMedWeb of Science®Google Scholar 88 Levy S, Todd SC, Maecker HT. CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol 1998; 16: 89–109. MEDLINE 10.1146/annurev.immunol.16.1.89 CASPubMedWeb of Science®Google Scholar 89 Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, Monk P, Higginbottom A, et al. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol 1999; 73: 6235–6244. MEDLINE 10.1128/JVI.73.8.6235-6244.1999 CASPubMedWeb of Science®Google Scholar 90 Shimizu YK, Iwamoto A, Hijikata M, Purcell RH, Yoshikura H. Evidence for in vitro replication of hepatitis C virus genome in a human T-cell line. Proc Natl Acad Sci U S A 1992; 89: 5477–5481. MEDLINE 10.1073/pnas.89.12.5477 CASPubMedWeb of Science®Google Scholar 91 Berger EA. HIV entry and tropism: the chemokine receptor connection. Aids 1997; 11(Suppl A): S3–S16. MEDLINE PubMedWeb of Science®Google Scholar 92 Browning J, Horner JW, Pettoello-Mantovani M, Raker C, Yurasov S, DePinho RA, Goldstein H. Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection. Proc Natl Acad Sci U S A 1997; 94: 14637–14641. MEDLINE 10.1073/pnas.94.26.14637 CASPubMedWeb of Science®Google Scholar 93 Allander T, Forns X, Emerson SU, Purcell RH, Bukh J. Hepatitis C virus envelope protein E2 binds to CD81 of tamarins. Virology 2000; 277: 358–367. MEDLINE 10.1006/viro.2000.0617 CASPubMedWeb of Science®Google Scholar 94 Meola A, Sbardellati A, Bruni Ercole B, Cerretani M, Pezzanera M, Ceccacci A, Vitelli A, et al. Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection. J Virol 2000; 74: 5933–5938. MEDLINE 10.1128/JVI.74.13.5933-5938.2000 CASPubMedWeb of Science®Google Scholar 95 Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 1999; 96: 12766–12771. MEDLINE 10.1073/pnas.96.22.12766 CASPubMedWeb of Science®Google Scholar 96 Wunschmann S, Medh JD, Klinzmann D, Schmidt WN, Stapleton JT. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J Virol 2000; 74: 10055–10062. MEDLINE 10.1128/JVI.74.21.10055-10062.2000 CASPubMedWeb of Science®Google Scholar 97 Ilan E, Burakova T, Dagan S, Nussbaum O, Lubin I, Eren R, Ben-Moshe O, et al. The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents. Hepatology 1999; 29: 553–562. MEDLINE 10.1002/hep.510290228 CASPubMedWeb of Science®Google Scholar 98 Galun E, Burakova T, Ketzinel M, Lubin I, Shezen E, Kahana Y, Eid A, et al. Hepatitis C virus viremia in SCID→BNX mouse chimera. J Infect Dis 1995; 172: 25–30. MEDLINE 10.1093/infdis/172.1.25 CASPubMedWeb of Science®Google Scholar 99 Bronowicki JP, Loriot MA, Thiers V, Grignon Y, Zignego AL, Brechot C. Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice. Hepatology 1998; 28: 211–218. MEDLINE 10.1002/hep.510280127 CASPubMedWeb of Science®Google Scholar 100 Gupta S, Chowdhury J. Hepatocyte Transplantation. New York: Raven, 1994. Google Scholar 101 Clayton DF, Darnell JE Jr., Changes in liver-specific compared to common gene transcription during primary culture of mouse hepatocytes. Mol Cell Biol 1983; 3: 1552–1561. MEDLINE 10.1128/MCB.3.9.1552 CASPubMedWeb of Science®Google Scholar 102 Clayton DF, Harrelson AL, Darnell JE Jr., Dependence of liver-specific transcription on tissue organization. Mol Cell Biol 1985; 5: 2623–2632. MEDLINE 10.1128/MCB.5.10.2623 CASPubMedWeb of Science®Google Scholar 103 Hanawa-Shimizu M, Maeno M, Shikata T. Transplantation studies on human and duck hepatocytes in athymic nude mice. Liver 1991; 11: 241–247. MEDLINE 10.1111/j.1600-0676.1991.tb00523.x CASPubMedWeb of Science®Google Scholar 104 Ponder KP, Gupta S, Leland F, Darlington G, Finegold M, DeMayo J, Ledley FD, et al. Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation. Proc Natl Acad Sci U S A 1991; 88: 1217–1221. MEDLINE 10.1073/pnas.88.4.1217 CASPubMedWeb of Science®Google Scholar 105 Rhim JA, Sandgren EP, Degen JL, Palmiter RD, Brinster RL. Replacement of diseased mouse liver by hepatic cell transplantation. Science 1994; 263: 1149–1152. MEDLINE 10.1126/science.8108734 CASPubMedWeb of Science®Google Scholar 106 Grompe M, Laconi E, Shafritz DA. Principles of therapeutic liver repopulation. Semin Liver Dis 1999; 19: 7–14. MEDLINE 10.1055/s-2007-1007093 CASPubMedWeb of Science®Google Scholar 107 Sandgren EP, Palmiter RD, Heckel JL, Daugherty CC, Brinster RL, Degen JL. Complete hepatic regeneration after somatic deletion of an albumin- plasminogen activator transgene. Cell 1991; 66: 245–256. MEDLINE 10.1016/0092-8674(91)90615-6 CASPubMedWeb of Science®Google Scholar 108 Petersen J, Dandri M, Gupta S, Rogler CE. Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma. Proc Natl Acad Sci U S A 1998; 95: 310–315. MEDLINE 10.1073/pnas.95.1.310 CASPubMedWeb of Science®Google Scholar 109 Grompe M, al-Dhalimy M, Finegold M, Ou CN, Burlingame T, Kennaway NG, Soriano P. Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev 1993; 7: 2298–2307. MEDLINE 10.1101/gad.7.12a.2298 CASPubMedWeb of Science®Google Scholar 110 Grompe M, Lindstedt S, al-Dhalimy M, Kennaway NG, Papaconstantinou J, Torres-Ramos CA, Ou CN, et al. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nat Genet 1995; 10: 453–460. MEDLINE 10.1038/ng0895-453 CASPubMedWeb of Science®Google Scholar 111 Overturf K, Al-Dhalimy M, Tanguay R, Brantly M, Ou CN, Finegold M, Grompe M. et al. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat Genet 1996; 12: 266–273. MEDLINE 10.1038/ng0396-266 CASPubMedWeb of Science®Google Scholar Citing Literature Volume33, Issue3March 2001Pages 489-495 ReferencesRelatedInformation
Referência(s)